Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06625320 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer
PDAC
PDAC - Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: RMC-6236
DRUG: Gemcitabine
DRUG: nab-paclitaxel
DRUG: Irinotecan
DRUG: Liposomal irinotecan
DRUG: 5-fluorouracil
DRUG: leucovorin
DRUG: Oxaliplatin

Sponsor

Revolution Medicines, Inc.